New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
07:30 EDTBMYBristol-Myers long-term thesis 'entirely unchanged,' says Citigroup
Citigroup said its long-term thesis on shares of Bristol-Myers is "entirely unchanged" after the stock sold off yesterday following safety and efficacy data for Yervoy plus nivolumab. Citi says it has always assumed minimal Yervoy combo use in lung cancer. It reiterates a Buy rating on the stock with a $60 price target.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use